COVID-19 + NanoFlu combination investigational vaccine

COVID-19 + seasonal influenza Vaccine Details
Therapeutic area
Infectious disease
Status
Technology
Respiratory diseases
COVID-19 + seasonal influenza
 
Phase 1/2
Matrix-M™ adjuvant
Therapeutic area
Respiratory diseases
Infectious disease
COVID-19 + seasonal influenza
Status
 
Phase 1/2
Technology
Matrix-M™ adjuvant

About the candidate

The Novavax COVID-NanoFlu combination investigational vaccine uses the full-length, stabilized recombinant spike (rS) protein of the SARS-CoV-2 virus, and 4 wild-type recombinant Hemagglutinin (rHA) proteins from the influenza virus, as antigens. Antigens are organized into distinct nanoparticle complexes recognized by the immune system, working in concert with our Matrix-M™ adjuvant.

Why it matters

Combination vaccines reduce the number of shots required to protect against multiple diseases. Simplifying immunizations into fewer shots may make it more likely that people get recommended vaccinations on time, reducing delays in protection.1,2 As both influenza and SARS-CoV-2 continue to circulate and evolve, combining these vaccines into a single shot could offer protection against both diseases. We believe that COVID-19 may become endemic and therefore may require seasonal vaccination, similar to the influenza vaccine.

  1. US CDC. Available at: https://www.cdc.gov/vaccines/parents/schedules/combination-vaccines.html [Accessed 27 Aug 2021].
  2. Skibinski D, et al. Glob Infect Dis. 2011;3(1):63–72. Available at: https://pubmed.ncbi.nlm.nih.gov/21572611/ [Accessed 4 Jan 2022].